Akero Therapeutics Inc
Company Overview
Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformational treatments for patients with serious metabolic diseases. The company's lead product candidate is efruxifermin (EFX), which is being developed for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease.
The company is currently in pre-revenue phase, focusing on research and development of its drug candidates through clinical trials. Akero operates primarily in the United States and is headquartered in South San Francisco, California.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Akero Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.